The Russian Gamaleya Research Institute has assured Sri Lankan authorities that the efficacy of the Sputnik V Covid 19 vaccine has been confirmed to be more than 91.4%, based on the final analysis of clinical trials.
The Sputnik-V vaccine was the world’s first registered Covid-19 vaccine and is currently in the final stages of its third clinical trial. This information was confirmed during an online meeting between the Ministry of Health of Sri Lanka, the Ministry of Health of Russia and the Gamaleya Research Institute of Epidemiology and Microbiology of the Ministry of Health of Russia held on December 29.
As the vaccine is during its final trials hoping to register the Covid-19 vaccine around the world, Sri Lankan and Russian experts in virology as well as top officials had met to discuss the Sputnik-V vaccine.
They had discussed the technology used to produce this vaccine, its safety and efficacy, the results of clinical trials and the status of approvals. The Sri Lankan side briefed the Russian experts on the research done in Sri Lanka on the changes in the virus and the Sri Lankan immunization program.
During the meeting, the Russian side assured that it was ready to share all necessary scientific data with Sri Lanka and to hold a series of further discussions to ensure that the Sri Lankan side receives all relevant information.
